InMed Pharmaceuticals Inc. is pleased to announce it has initiated testing of a novel nanoparticle-based delivery system for INM-750, which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder.
InMed’s development programmes for transdermal delivery will use a nanoparticle-based delivery system. The delivery system underwent investigation in in vitro and in vivo animal models and further studies are being conducted — based on the European norm “BS EN 13726-1: 2002” entitled test methods for wound dressings.
InMed anticipates commencing human proof of concept clinical studies of INM-750 in February 2016, with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US Food and Drug Administration (FDA).
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.